Edition:
United States

Cerus Corp (CERS.OQ)

CERS.OQ on NASDAQ Stock Exchange Global Market

4.27USD
28 Mar 2017
Change (% chg)

$0.05 (+1.18%)
Prev Close
$4.22
Open
$4.25
Day's High
$4.27
Day's Low
$4.25
Volume
15,322
Avg. Vol
221,253
52-wk High
$7.64
52-wk Low
$3.79

Latest Key Developments (Source: Significant Developments)

Cerus reports Q4 loss per share of $0.13
Tuesday, 7 Mar 2017 04:01pm EST 

Cerus Corp : Cerus Corp reports fourth quarter and year end 2016 results . Q4 loss per share $0.13 . Q4 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S . Company expects 2017 global product revenue in range of $45 million to $50 million .Says product revenue for Q4 of 2016 was $10.1 million, compared to $9.7 million recognized during same period in 2015.  Full Article

Cerus Corp reports Q3 loss per share $0.14
Thursday, 3 Nov 2016 04:01pm EDT 

Cerus Corp : Continues to expect 2016 global product revenue in range of $37 million to $40 million . Cerus corporation reports third quarter 2016 results . Q3 loss per share $0.14 .Q3 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S.  Full Article

Cerus announces first U.S. Blood center customer submits biologics license application
Thursday, 13 Oct 2016 08:30am EDT 

Cerus Corp : Cerus announces first U.S. Blood center customer submits biologics license application to the FDA to allow for interstate export of intercept platelet components .Cerus -community blood center of Appleton, Wisconsin has submitted first biologics license application to U.S FDA.  Full Article

FDA recommends use of pathogen reduction for universal Zika risk reduction of blood components
Monday, 29 Aug 2016 08:30am EDT 

Cerus Corp : Fda's new recommendation for universal zika risk reduction of blood components includes use of pathogen reduction .Use of pathogen reduction, such as intercept blood system for platelets and plasma, is specified as an acceptable safety measure.  Full Article

Cerus Q2 loss per share $0.18
Thursday, 4 Aug 2016 04:01pm EDT 

Cerus Corp : Q2 loss per share $0.18 . Q2 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S . Cerus corporation reports second quarter 2016 results . Q2 revenue $9.3 million versus i/b/e/s view $8.9 million . Sees fy 2016 revenue $37 million to $40 million .Fy2016 revenue view $38.7 million -- Thomson Reuters I/B/E/S.  Full Article

Cerus Corp signed multi-year purchase agreement for INTERCEPT Blood System
Tuesday, 9 Feb 2016 08:30am EST 

Cerus Corp:Says American Red Cross has signed a multi-year purchase agreement for the INTERCEPT Blood System for platelets and plasma.  Full Article

Cerus Corp announces agreement with Blood Systems Inc
Tuesday, 5 Jan 2016 08:30am EST 

Cerus Corp:Has signed a master agreement with Blood Systems Inc for use of INTERCEPT blood system for platelets and plasma.  Full Article

Cerus Corp and OneBlood enter into agreement for the use of INTERCEPT Platelets and Plasma
Thursday, 5 Nov 2015 08:30am EST 

Cerus Corp:Says co and oneblood enter into agreement for the use of intercept platelets and plasma.  Full Article

Cerus Corp announces new agreement with Fresenius Kabi for production of INTERCEPT Blood System Kits
Wednesday, 21 Oct 2015 08:30am EDT 

Cerus Corp:Says has signed agreement with Fresenius Kabi.Says 10-year contract extends and reinforces the existing partnership for the production of INTERCEPT Blood System kits at the manufacturing facility in La Châtre, France.Under terms of the agreement, Fresenius Kabi has committed to investing in the La Châtre facility.Agreement also provides that should the volume expectations require, second manufacturing facility would be identified and qualified.Under the new agreement, the current license agreement with Fresenius Kabi will convert to a royalty-free license and Cerus will no longer be required to pay royalties on the sale of INTERCEPT kitss.  Full Article

Cerus Corp reaffirms FY 2015 revenue guidance
Tuesday, 11 Aug 2015 04:01am EDT 

Cerus Corp:Sees FY 2015 revenue to be driven by core European and Middle Eastern markets, for which the company maintaining revenue guidance of $36-38 million.  Full Article

More From Around the Web

BRIEF-Cerus reports Q4 loss per share of $0.13

* Cerus Corp reports fourth quarter and year end 2016 results